Negative Phase III trial casts some doubt on Erbitux's role in first-line colorectal cancer
This article was originally published in Scrip
Executive Summary
An independently sponsored European Phase III trial (NORDIC VII) testing Merck KGaA/Lilly/Bristol-Myers Squibb's Erbitux (cetuximab) in first-line, metastatic colorectal cancer (mCRC) has failed to show a survival benefit with the EGFR-targeted monoclonal antibody, not even in the subpopulation of KRAS wild-type patients where a benefit was expected.